Digital Therapeutics: The New Route Post COVID-19 

About this Content

Digital therapeutics (DTx) is the delivery of evidence-based therapeutic interventions to patients via high-quality software programs in order to prevent, manage, or treat a wide variety of physical, mental, and behavioral conditions, as defined by the Digital Therapeutics Alliance. It has the potential to:

• Enhance and support current medical treatments
• Provide patients, providers, and payers with novel therapy options for unmet medical needs
• Be used independently or in conjunction with other therapies
• Reduce reliance on certain pharmaceuticals or other therapies
• Integrate into medical guidelines and best practices

The convergence of technology and healthcare to reach patients digitally and provide them with high-quality care is attracting investments in the DTx sector. DTx companies in the U.S. have grown by an average of 40% a year over the past 7 years, with DTx application trials increasing more than 5 times from 12 in 2015 to 58 in 2019. Organizations wanting to invest in digital therapeutics for end-to-end disease management can either opt for complementary pairing/Strategic partnerships or acquisitions.

Grow alongside the healthcare industry and capitalize on the coming waves of technology innovation.